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Patient survival after renal transplantation: I. The impact of dialysis
pre-transplant. Patients on dialysis and recipients of renal transplants
have higher mortality than individuals without kidney disease. In this study
we evaluated the possible impact of dialysis therapy before transplantation
on patient survival after the transplant. This analysis includes all of the
patients who received a cadaveric renal transplant at The Ohio State
University from 1984 to 1991 and who remained alive with functioning
grafts for at least six months after the transplant (N 5 523). After a
follow-up of 84 6 14 months, 28% of the patients died and 23% lost their
grafts. By multivariate analysis, reduced patient survival (censored at the
time of graft loss) correlated with these pre-transplant variables: Older age
(P , 0.0001), the presence of diabetes (P 5 0.0002), smoking (P 5 0.009),
and the length of time on dialysis (P 5 0.0002). Thus, 7% of patients who
were never dialyzed, 23% of those dialyzed for less than three years, and
44% of patients dialyzed for $ three years died post-transplant. By Cox
regression, patient survival months correlated with time on dialysis
pre-transplant (P 5 0.0003). The type of dialysis (CAPD vs. hemodialysis)
did not correlate with patient survival. Graft survival, censored for patient
death, did not correlate with any of these pre-transplant variables. The
relationship between time on dialysis and patient mortality is due to at
least two factors: (1) transplant recipients who had dialysis for $ 3 years
had higher mortality due to infections (22%) than those who had dialysis
for , 3 years (3%, P 5 0.01 by X2); and (2) increasing time on dialysis
increases the prevalence of both left ventricular hypertrophy (P 5 0.008)
and cardiomegaly (P 5 0.004), and these relationships are statistically
independent of other factors that also correlate with the prevalence of
cardiovascular disease. In conclusion, increased time on dialysis prior to
renal transplantation is associated with decreased survival of transplant
recipients.
Despite dramatic advances in the field of renal transplantation,
patient death continues to be a leading cause of renal transplant
failure. In fact, in selected patient populations, such as in patients
with diabetes [1, 2] and in smokers [3], patient death is the most
common reason for renal transplant loss. The excess mortality of
transplant recipients is mainly due to cardiovascular causes [4].
Several factors contribute to the excessive cardiovascular risk of
renal transplant recipients, and these factors can be subdivided
into two categories: (1) factors that are introduced at the time of
transplantation, for example, worsening hypertension, hyperlipid-
emia and administration of corticosteroids; and (2) cardiovascular
factors that are already present in the patient before the trans-
plant. In fact, the evidence suggests that perhaps the majority of
patients with renal disease acquire cardiovascular abnormalities
prior to the initiation of dialysis, and that dialysis accelerates the
development of cardiovascular disease. This evidence is as fol-
lows. Prior to the initiation of dialysis, patients frequently have
evidence of cardiovascular disease, such as left ventricular hyper-
trophy (LVH), dilated cardiomyopathy, and history of congestive
heart failure. The presence of some of these cardiovascular
markers predict patient survival on dialysis [5–7]. Several studies
have shown that prior to dialysis, the prevalence of LVH increases
with increasing age, worsening renal function, anemia, and hyper-
tension [8–10]. Sequential studies in patients maintained on
hemodialysis indicate that the patient’s cardiovascular risk profile
may worsen with time on dialysis, particularly in patients with
poorly controlled blood pressure (BP) [11, 12]. The modality of
dialysis may also have implications for cardiovascular risk and/or
patient survival. Several studies have shown that the mortality of
patients on continuous peritoneal dialysis (CAPD) exceeds that of
patients on hemodialysis (HD) [13, 14]. In apparent contrast with
this observation, LVH is significantly more common in patients on
HD than those on CAPD [15].
Based on the observations discussed above, in these studies we
assessed whether patient survival post-transplant correlates with:
(1) the length of time that the patient was treated with dialysis
prior to the transplant, and/or (2) the type of dialysis that the
patient received. The implications that these determinations may
have for the care of the patient with end stage-renal disease are
clear. However, initially one may conclude that there is little we
can do to shorten the dialysis time pre-transplant, because most
often the waiting period for renal transplantation is caused by the
shortage of donor organs. However, it is our anecdotal experience
that some patients are referred for renal transplantation only after
they have been on dialysis for a certain period of time. Further-
more, there is sufficient evidence to conclude that improvements
in the delivery of dialysis will reduce patient morbidity and
mortality [16, 17], and the results of these studies suggest that
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improvements in dialysis delivery will also improve patient sur-
vival post-transplant.
METHODS
The population of patients studied here included all adult
cadaveric kidney transplant recipients transplanted at The Ohio
State University from August 1984 to November 1991. In addi-
tion, these patients met the following criteria. (1) Patients were
alive with a functioning graft for at least six months following the
transplant. (2) For patients alive with functioning allografts, the
minimum period of follow-up was six years. (3) All patients were
followed at our institution. The exclussion of patients who died
shortly after transplantation was done in an effort to exclude
surgical complications as a cause of death, because the main focus
of this study was on long term patient mortality. Following
transplantation, patients were treated with a uniform immunosup-
pressive protocol that has been previously described [18]. Briefly,
immediately following the transplant, patients received induction
immunosuppressive therapy with Minnesota anti-lymphocyte
globulin or OKT3 (Ortho Biotech), azathioprine, and prednisone.
Subsequently, once the patient’s serum creatinine reached a
concentration of 2.5 mg/dl or lower, the patient was started on
cyclosporine (CsA) and maintained on combined therapy with
prednisone and cyclosporine for the length of the follow-up.
Those patients who required re-initiation of chronic dialysis
therapy were considered as allograft failures.
Pre-transplant variables were collected by a review of outpa-
tient and inpatient charts. Patients transplanted at our institution
are referred from a rather wide geographic area covering princi-
pally Central and Southeast portions of the state of Ohio, portions
of Kentucky and West Virginia. These patients received their
pre-transplant medical care in several dialysis units and the care
was provided by several nephrologists. Thus, the results of this
analysis is likely to be representative of the effects of dialysis in
our region and does not reflect the effects of dialysis care in a
single center. The routine pre-transplant cardiovascular evalua-
tion included an electrocardiogram (EKG) and a chest x-ray
(CxR). A cardiac ultrasound was not done routinely as part of the
pre-transplant evaluation. Consequently, the diagnoses of cardi-
omegaly in this study was based on radiologic criteria that is, the
presence of a cardial silhouette that occupies more than 50% of
the thoracic transverse diameter. The diagnosis of LVH was made
by ECG, and were interpreted electronically by the Marquette
Medical Systems (Marquette Electronics Inc, WI,), which is based
principally on voltage criteria of LVH [19]. Furthermore, all ECG
tracings were reviewed by cardiologists at Ohio State University
who customarily made the diagnosis of LVH based on published
criteria [20]. Pre-transplant blood pressure (BP) levels were
collected at several time points including prior to dialysis, during
hospitalization prior to the transplant, and during the patient’s
pre-transplant work-up. All of these BP levels were averaged and
the mean arterial pressure (MAP) was calculated by the following
formula: [(systolic BP-diastolic BP)/3) 1 diastolic BP]. Post-
transplant parameters were retrieved from a computerized data-
base that included all post-transplant laboratory tests, BP record-
ings, and hospitalizations. Blood pressure levels were measured by
the patient at home and the results called to our transplant center.
The diagnosis of acute rejection, in our institution, is always based
on both clinical (that is, acute elevation of serum creatinine) and
pathologic criteria [21].
The cause of the patient’s demise was obtained from diagnoses
included in the patient’s death certificate, and these data were
obtained from files maintained in the United States Renal Data
System (USRDS) [14]. Information on the primary cause of death
was available in 101 of the 144 patients who died (70%). However,
information on secondary causes of death was available in only
very few patients, and for this reason these latter data were not
analyzed.
Statistical analysis
Values are expressed as means 6 SD throughout the manu-
script. The means of normally distributed data were compared by
Student’s t-test, and when the data were not normally distributed,
by non-parametric test (Mann-Whitney). Chi square was used to
compare percentages. Linear regression and non-parametric cor-
relations (Spearman) were used to analyze relationships among
data. Cox proportional hazards and Kaplan-Meier plots were used
to estimate patient and graft survival. Patient survival was cen-
sored at the time of allograft loss. Graft survival was analyzed with
and without censoring for patient death as it will be indicated.
RESULTS
Patient characteristics pre-transplant
Table 1 displays the patient characteristics. By study design, all
patients were alive and had functioning renal grafts for at least six
months post-transplant. The average period of follow-up for the
population was 84 6 41 months. During this period, 28% of the
patients died and 23% lost their graft for causes other than patient
death.
Relationships between pre-transplant variables and patient
survival
Table 2 displays results of univariate and multivariate correla-
tions between pre-transplant variables and patient survival. As can
be seen, reduced patient survival correlated with increasing age,
Table 1. Patient characteristics prior to transplantation
Parameters Value
Number of patients 523
Age years 43 6 13
Gender % males 59%
Race % Caucasians 78%




LVH by EKG 28%
Dialysis time months 17.6 6 18
Dialysis type
No dialysis 29 (6%)
Hemodialysis (HD) 319 (66%)
CAPD 96 (20%)
HD/CAPD 38a (8%)




a Thirty-six patients had HD first and then CAPD; 2 patients had CAPD
first and then HD
b Percent of patients with MAP $ 107 mm Hg (;140/90). The majority
of these patients were taking antihypertensive medications (4,257) at the
time of determination of BP.
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diagnosis of diabetes, smoking, the presence of cardiomegaly, and
increasing periods of time on dialysis. By multivariate analysis,
older age, the presence of diabetes, a history of smoking, and the
length of time on dialysis correlated significantly with patient
mortality (Table 2). In contrast, cardiomegaly did not correlate
with patient mortality as long as the parameter “time on dialysis”
was also incorporated in the multivariate model. However, if this
latter parameter was excluded from the model, cardiomegaly
correlated with patient mortality independently from age, smok-
ing, or diabetes. Blood pressure levels, analyzed as systolic BP or
as MAP did not correlate with patient mortality post-transplant
(Table 2).
The relationship between time on dialysis and patient survival is
displayed graphically in Figure 1. To further analyze the effect of
time on dialysis on patient survival, patients were divided into
three groups: (1) 29 patients never received dialysis prior to the
transplant; (2) 342 patients were on hemodialysis or CAPD for
one to two years; and (3) 91 patients had received dialysis (any
modality) for at least three years. In the remaining patients we
could not precisely determine the time they had spent on dialysis.
Patient mortality among these three groups of patients were 7%,
23% and 41%, respectively (P , 0.0001, X2). It should be noted
that patients who had been maintained on dialysis for relatively
short periods of time (1 to 2 years) had a significantly higher
mortality than patients who never received dialysis, although that
latter group of patients is small (mortality in group 1 vs. group 2,
P , 0.04 by X2). By the Cox regression, the length of patient
survival after the transplant was also significantly different among
these three groups of patients (P 5 0.0003). Figure 2 displays
Kaplan-Meier plots of patient survival in these three groups of
recipients.
The modality of dialysis had no statistically significant effect on
patient mortality (Table 2). Thus, 17% of the patients who
received CAPD and 23% of the patients who received HD died
after transplantation (NS). In contrast, 43% of the 38 patients
who received both HD and CAPD prior to the transplant died,
and the mortality rate of these individuals is significantly higher
than the mortality rate of patients who received HD alone (23%,
P 5 0.01 by X2) or CAPD alone (17%, P 5 0.003 by X2). The
higher mortality of patients who received both HD and CAPD
could not be explained by differences in age, smoking, length of
time on dialysis, or the prevalence of LVH or cardiomegaly.
Patient survival did not correlate significantly with the following
post-transplant parameters (collected during the first six months
following the transplant): allograft function, number of rejection
episodes, average BP levels, lipid levels (total cholesterol or
triglycerides), or cumulative doses of prednisone or cyclosporine.
Because patient survival was censored at the time of graft loss,
it is important to note that none of the parameters listed in Table
2, and in particular time on dialysis, correlated statistically with
death-censored graft survival (data not shown). However, pre-
transplant variables had important consequences for the overall
success of renal transplantation. For example, increasing time on
dialysis correlated with shorter renal allograft survival, when the
graft survival data were not death censored (Fig. 3A; Cox
Table 2. Correlation between pre-transplant variables and patient











Blood pressurea NS —
LVH by EKG NS —
Cardiomegaly 0.0005 NSb
Smoking 0.004 0.009
Type of dialysis NS —
Time on dialysis 0.0005 0.0002
Analyses were done by univariate and multivariate logistic regression
analysis.
a Blood pressure was analyzed as systolic BP or MAP with similar results
b The variable cardiomegaly was not significantly correlated with sur-
vival if “time on dialysis” was included in the multivariate model
Fig. 1. Relationship between time on dialysis (x axis) and patient sur-
vival after renal transplantation. The number of patients in each group is
according to their duration on dialysis: 0 year, N 5 29; 1 year, N 5 205; 2
years, N 5 137; 3 years, N 5 45; $ 4 years, N 5 46.
Fig. 2. Kaplan-Meier plots of patient survival. Patients were divided into
three groups according to the time that they had spent on dialysis (any
modality) prior to transplantation: No dialysis (–); 1 to 2 years (1⁄4); or $
three years ( ). Cox regression: P 5 0.0003.
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regression, P 5 0.003). In this analysis, graft survival was signifi-
cantly better in patients who never received dialysis than in those
who had dialysis for one to two years (Cox regression, P 5 0.04),
and graft survival was also significantly better in patients who
received dialysis for one to two years than in those who received
dialysis for longer periods of time (Cox regression, P 5 0.03). In
contrast to these results, the time on dialysis did not correlate
significantly with death-censored graft survival (Fig. 3B; Cox
regression, P 5 0.6).
Relationship between time on dialysis and cardiovascular
factors
To try to determine the reason for the association between time
on dialysis and patient mortality, we evaluated the pre-transplant
characteristics of patients divided according to the time they had
spent on dialysis (Table 3). As can be seen, the prevalence of LVH
increased with increasing time on dialysis (any modality) (P 5
0.01 by X2 and P 5 0.003 by logistic regression). Similarly, the
prevalence of cardiomegaly also increased with time on dialysis
(P 5 0.007 by X2 and P 5 0.0006 by logistic regression).
Because other factors contribute to the development of cardio-
vascular factors, we next assessed whether the relationship be-
tween time on dialysis and cardiovascular parameters is related to
some of these other covariates. Table 4 displays univariate and
multivariate analysis of the relationships between pre-transplant
variables and cardiomegaly or LVH. As can be seen the preva-
lence of these cardiovascular abnormalities increases with increas-
ing age, Black race, elevated BP levels, and increasing time on
dialysis. Furthermore, the prevalence of LVH was significantly
higher in males (33%) than in females (21%, P 5 0.004, by X2);
and in patients treated with HD (33%) compared to those treated
with CAPD (23%, P 5 0.04 by X2). By multivariate analysis
(Table 4), the relationship between time on dialysis and cardio-
megaly is statistically independent from other factors associated
with this cardiovascular marker. Similarly, the relationship be-
tween time on dialysis and LVH is statistically independent from
other correlates of LVH.
Causes of death
Analysis of the primary cause of death reported in the patient’s
death certificate (Table 5) showed that death due to infection was
significantly more common in patients maintained on dialysis for
Fig. 3. (A) Graft survival in kidney transplant recipients divided accord-
ing to the time that the patient was on dialysis prior to the transplant: no
dialysis (–); 1 to 2 years of dialysis (1⁄4); 3 years on dialysis ( ) by Cox
regression, P 5 0.003; (B) death censored kidney graft survival (Cox
regression, NS). Patients were divided into the same groups described
in A.
Table 3. Patient’s characteristics according to the period of time that
they spend on dialysis prior to transplantation
Parameter
Time on dialysis (years)
Statisticsa0 1–2 $3
Number of patients 29 342 91
Age 42 6 13 43 6 12 44 6 14 NS
Gender % Males 48% 37% 44% NS
Race % Blacks 21% 20% 32% .05
Weight kg 73 6 16 72 6 16 70 6 20 NS
Diabetes 21% 27% 21% NS
Smoking 46% 43% 35% NS
Blood pressure 109 6 10 108 6 14 108 6 13 NS
LVH by EKG 14% 26% 39% 0.01b
Cardiomegaly 15% 31% 45% 0.007c
Type of dialysis % HD — 68% 78% NS
a Proportions were compared by Chi square and means were compared
by ANOVA
b P 5 0.003 by logistic regression analysis
c P 5 0.0006 by logistic regression analysis
Table 4. Pre-transplant variables that correlate with the prevalence of
cardiomegaly or LVH prior to transplantation
Parameter
Cardiomegaly LVH
Univariate Multivariate Univariate Multivariate
Age 0.004 NS 0.03 NS
Race ,0.0001 0.001 ,0.0001 0.001
Gender NS — 0.004 0.006
Weight NS — NS —
Diabetes NS — NS —
Blood pressure
(systolic)
0.005 0.01 0.0002 0.001
Smoking NS — NS —
Type of dialysis NS — 0.03 0.04
Time on dialysis 0.0006 0.004 0.003 0.008
Univariate and multivariate logistic regression analyses were used.
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three or more years (21%) compared to those maintained on
dialysis for less than three years (4%). The prevalence of all other
causes of death was not statistically different between both groups
of patients. Analysis of specific cardiovascular causes of death, for
example, acute myocardial infarction or cardiopulmonary arrest,
did not disclose significant differences between patients dialyzed
for less or more than two years (data not shown). The group of
patients that did not receive dialysis included only two patients
who died, and thus, it was not possible to compare the causes of
death in patients who received dialysis prior to the transplant and
those who did not.
DISCUSSION
The findings of this study emphasize the need to consider the
mortality of patients with end-stage renal disease (ESRD) as the
result of the accumulation of risk factors starting at the time of
initiation of renal disease, worsening as the renal function de-
creases [5], and progressing when dialysis is initiated [11]. Previ-
ous studies have shown that the mortality of patients who received
renal transplants is significantly lower than the mortality of
patients on dialysis (such as [14]), suggesting that transplantation
may reverse, at least partially, the factors that cause the high
mortality of dialysis patients. Consistent with this postulate,
studies by Parfrey et al [22] indicate that left ventricular mass
decreases following renal transplantation. However, this benefi-
cial effect of renal transplantation is partially negated by the
introduction of new risk factors, such as worsening of blood
pressure control [23], immunosuppressants, etc. Despite the ben-
eficial and detrimental effects of transplantation, the results of
this study indicate that pre-transplant variables still predict pa-
tient survival after renal transplantation.
These results confirm the findings of several previous studies
showing that among transplant recipients, older patients [24] and
those with diabetes [25] have a higher mortality than younger and
nondiabetic patients, respectively. In addition, these studies em-
phasize the impact of at least two additional pre-transplant factors
on patient mortality: (1) increasing time on dialysis; and (2)
smoking. The impact of smoking on patient survival post-trans-
plant will be addressed in a separate manuscript [3]. The conse-
quences of dialysis are such that even relatively short periods of
time on dialysis (1 to 2 years) are associated with a significant
increase in patient mortality and an increase in failure of renal
transplantation due to patient’s demise. It can be argued that
these findings may be due to patient selection, because perhaps
younger and healthier patients with ESRD may be transplanted
sooner than other patients. However, this argument is not sup-
ported by these data. For example, there were not significant age
differences between patients who received dialysis and those who
did not. In addition, although patients who received dialysis have
a higher prevalence of LVH and cardiomegaly, these data and
other studies suggest that this association is due to worsening of
cardiovascular disease with time on dialysis (Table 4 and [11]) and
not due to patient selection.
These results suggest that cardiomegaly (by CxR) is a better
predictor of patient survival than LVH (by EKG). However, the
interpretation of these data are limited by the fact that in these
studies the precise anatomy of the left ventricle was not defined by
cardiac ultrasound. Indeed, previous studies have shown that the
geometry of the LV correlates with patient survival on dialysis [6].
Because cardiomegaly correlates with patient survival, and be-
cause increasing time on dialysis is associated with a higher
prevalence of cardiomegaly, it is likely that cardiovascular factors
explain, at least in part, the relationship between time on dialysis
and patient survival. This postulate was not confirmed by exami-
nation of the cause of death specified in death certificates.
However, this analysis is limited for at least two reasons: (1) We
were unable to obtain information about the cause of death in
30% of the patients; and (2) We suspect that cardiovascular
diagnoses included in death certificates are frequently presumed
rather than proven. Based on these two reasons, we would not
dismiss the postulate that time on dialysis pre-transplant increases
the cardiovascular risk of renal transplant recipients, and thus
their mortality.
This study also showed that patients maintained on dialysis for
more than three years demonstrate higher mortality due to
infectious causes than patients on dialysis for a shorter period of
time. We give credence to this observation because it is likely that
the inclusion by a physician of the diagnosis of “death due to
infection and/or sepsis” in a death certificate is most likely based
on objective evidence of active infection at the time of patient’s
death. Furthermore, there is abundant evidence in the literature
that renal failure and/or dialysis has immunosuppressive effects
[26, 27], and in fact, infection is only second to cardiac arrest as
the single most common cause of death in patients with ESRD,
particularly those on dialysis [14]. It is also quite possible that the
higher rate of infections in patients maintained on dialysis for
prolonged period of time may be related to malnutrition that is a
frequent complication of prolonged dialysis therapy. Malnutrition
can be assessed by measuring serum albumin levels [28, 29].
Unfortunately, results of albumin levels pre-transplant were not
available for analysis in this study. Consistent with these results,
previous studies showed that in recipients of kidney-pancreas
allografts, graft loss due to infection was significantly higher in
patients who received dialysis pre-transplant compared to those
patients who did not receive dialysis [30].
The type of dialysis that the patient received prior to transplan-
tation did not correlate with survival. However, it is of interest
that patients who were switched from HD to CAPD had a higher
mortality than any of the other groups of patients included in this
study. The reasons for the high mortality of this patient group is
unclear, but this analysis did not disclose significant differences
between these patients and others in the prevalence of variables
that correlate with patient survival. We postulate that the high
mortality of patients who received both HD and CAPD indicates
Table 5. Causes of death post-transplant in patients who had been




$3 years Chi square
Number of patients 57 24
Cause of death
CardiovascularB 30 (53%) 9 (38%) NS
Cerebrovascular 4 (13%) 3 (13%) NS
Infections 3 (4%) 5 (21%) 0.01
Malignancy 3 (5%) 1 (4%) NS
Other 8 (14%) 3 (13%) NS
Unknown cause 10 (18%) 3 (13%) NS
B Includes in descending order of prevalence: acute myocardial infarc-
tion, cardiopulmonary arrest, arrhythmia, other cardiovascular causes, and
atherosclerotic heart disease.
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that other pre-transplant factors not considered here, also corre-
late with patient survival [31].
Since 1991 (the most recent transplant year in the population of
patients included in this study) important changes have been
introduced in the practice of dialysis, and it is reasonable to expect
that those changes will cause a reduction in patient morbidity and
mortality [14, 17]. However, it is of concern that this recent
emphasis in improving dialysis treatment by increasing solute
clearance has not been associated with an equal emphasis in
improving blood pressure and volume control, parameters that
clearly correlate with the development of cardiovascular disease
in ESRD patients [11]. It is likely that differences in the quality of
the dialysis treatment and in the control of other cardiovascular
risk factors explain the rather stricking differences in patient
mortality among dialysis centers [16]. This study predicts that
improvements in the quality of dialysis treatment are likely to
improve not only patient survival during dialysis but also after
transplantation.
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